Natixis Advisors, L.P. Prothena Corp Public LTD CO Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding PRTA
# of Institutions
184Shares Held
42.7MCall Options Held
162KPut Options Held
102K-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$158 Million8.41% of portfolio
-
Wellington Management Group LLP Boston, MA4.18MShares$57.1 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.86MShares$52.7 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$52.3 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.74MShares$23.8 Million4.0% of portfolio
About PROTHENA CORP PUBLIC LTD CO
- Ticker PRTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,922,800
- Market Cap $641M
- Description
- Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...